Every Biosimilar Should Have Its Own Medicare Pay Code, CMS Told
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz and other biosimilar stakeholders react at a public meeting to indications that CMS might be planning to put multiple biosimilars into a single Medicare billing code, meaning they would all be reimbursed at the same amount, when they reference the same innovator product.
You may also be interested in...
CMS’ Likely Reversal Of Threat To Part D Protected Classes Doesn’t Mean Other Reforms Aren’t Coming
Concerns about reducing patient protections will resonate with the Biden Administration and the Medicare Part D protected classes aren’t major cost drivers anyway, Avalere’s Mendelson says.
Insurer Seeks To Recover ‘Illegal’ Daraprim Overcharges Due To Obstruction Of Generics
Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.
Tie Goes To The Nominee: Becerra Heads To Senate Floor
Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: